Drug intelligence / Profile preview

LP-211

Development stage
Unknown
Lead developer
University of Bari Aldo Moro
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

LP-211 is a brain-penetrant, selective **serotonin 5-HT7 receptor agonist** with high potency and selectivity. It exhibits a Ki value of **0.58 nM** at rat cloned 5-HT7 receptors and demonstrates over **300-fold selectivity** over the 5-HT1A receptor[1][3]. The compound functions as a **full agonist** at the 5-HT7 receptor, showing 82% maximal activity compared to 5-CT with an EC50 value of 0.60 μM[1]. LP-211 undergoes metabolic N-dealkylation to form **RA-7** (1-(2-diphenyl)piperazine), an active metabolite that concentrates in the brain and possesses even higher 5-HT7 receptor affinity (Ki = 1.4 nM) than the parent compound[1]. The compound has been developed as a research tool for investigating 5-HT7 receptor function and has demonstrated effects on body temperature regulation, novelty preference, and risk-prone behavior in preclinical studies. LP-211 was synthesized at the **Dipartimento Farmaco-Chimico, Università degli Studi di Bari**[1].

Other names
N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide
02

Targets

HTR7 (5-hydroxytryptamine receptor 7)

Beyond the preview

Go deeper on LP-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-211.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call